# Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/receptor-tyrosine-kinase-fusions-and-braf-kinase-fusions-are-rare-but-actionable/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Alexa B. Schrock,Viola W. Zhu,Wen-Son Hsieh,Russell W. Madison,Ben Creelan,Jeffrey Silberberg,Dan Costin,Anjali Bharne,Ioana Bonta,Thangavijayan Bosemani,Petros Nikolinakos,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Samuel J. Klempner,Sai‐Hong Ignatius Ou |
| Citations | 137 |
| DOI | 10.1016/j.jtho.2018.05.027 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jtho.2018.05.027 |
| OpenAlex ID | https://openalex.org/W2805346544 |
| PMID | 29883838 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Ben Creelan](https://scholariq.org/researchers/ben-creelan/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.